Robocath02.17.22
The first one for R-One was a good one.
Robocath's surgical robot performed its first carotid stenting procedure in France as part of a research program launched in 2020 by the company and Rennes University Hospital, in partnership with Philips France. Neurointerventionalist François Eugène, M.D., used R-One to perform the procedure at Rennes University Hospital. The carotid stenting procedure is part of a clinical study designed to enrich current and future generations of robotic platforms, and improve stroke treatment.
“I am honored to be one of the first operators in the world working in neurovascular robotics. Until now, there were no clinical investigations in Europe in this area, despite all its potential benefits," Eugène said. "Every year, 5.5 million people around the world die from a stroke, and one in two stroke victims live with lifelong consequences. The reason for this is a lack of comprehensive health coverage, due to a shortage of qualified operators and hospitals capable of performing this type of procedure. Strokes must be treated quickly but also with extreme precision. Robotics can operate with millimeter accuracy and offer new possibilities in terms of movement, as well as bringing more comfortable working conditions. In time, I am sure that robotic assistance will provide the population with optimal stroke treatment and equality of access to care in France, as well as in other countries facing the same public health issues.”
R-One is the first solution developed by Robocath. It uses a unique bionic technology that optimizes the safety of robotic-assisted coronary angioplasty. This medical procedure consists of revascularizing the cardiac muscle by inserting one or more implants (stents) into the arteries that supply it with blood. Every 30 seconds, somewhere in the world, this type of procedure is performed. R-One is designed to operate with precision and perform specific movements, creating better interventional conditions. Thanks to its open architecture, R-One is compatible with market-leading devices and cath labs.
“Strokes are currently the second most common cause of death worldwide. However, there is huge inequality in terms of care provision. The success of treatment is highly dependent on the operator’s level of experience and the proximity of a center capable of treating the condition. Our robotic solution will enable procedures to be more precise and more reliable, which will benefit stroke patients by greatly improving their treatment. Linked with our remote connection module, in the future our technology could treat 100 percent of patients in the best possible conditions,” Robocath CEO Lucien Goffart said.
In a prospective, randomized, controlled pre-clinical trial, R-One demonstrated safety and efficacy as it achieved 100 percent technical procedure success and no major adverse cardiovascular events. R-One received CE marking in February 2019 and started its clinical application in September 2019. Currently R-One is available in Europe and Africa.
“Robocath’s founding ambition was to ensure the best possible treatment for all stroke patients. For the first time in the company’s history, this procedure has made that ambition a reality," Robocath President/Founder Philippe Bencteux said. "It is a major step forward in our development; opening up some very promising new possibilities for our next robotic generation. I would like to thank Dr. Eugène for his involvement. With his support, as well as that of Philips France, we intend to showcase the huge potential of robotics in the neurovascular field.”
Founded in 2009, Robocath designs, develops, and commercializes robotic solutions to treat cardiovascular diseases. Based in Rouen, France, Robocath has more than 60 employees.
Robocath's surgical robot performed its first carotid stenting procedure in France as part of a research program launched in 2020 by the company and Rennes University Hospital, in partnership with Philips France. Neurointerventionalist François Eugène, M.D., used R-One to perform the procedure at Rennes University Hospital. The carotid stenting procedure is part of a clinical study designed to enrich current and future generations of robotic platforms, and improve stroke treatment.
“I am honored to be one of the first operators in the world working in neurovascular robotics. Until now, there were no clinical investigations in Europe in this area, despite all its potential benefits," Eugène said. "Every year, 5.5 million people around the world die from a stroke, and one in two stroke victims live with lifelong consequences. The reason for this is a lack of comprehensive health coverage, due to a shortage of qualified operators and hospitals capable of performing this type of procedure. Strokes must be treated quickly but also with extreme precision. Robotics can operate with millimeter accuracy and offer new possibilities in terms of movement, as well as bringing more comfortable working conditions. In time, I am sure that robotic assistance will provide the population with optimal stroke treatment and equality of access to care in France, as well as in other countries facing the same public health issues.”
R-One is the first solution developed by Robocath. It uses a unique bionic technology that optimizes the safety of robotic-assisted coronary angioplasty. This medical procedure consists of revascularizing the cardiac muscle by inserting one or more implants (stents) into the arteries that supply it with blood. Every 30 seconds, somewhere in the world, this type of procedure is performed. R-One is designed to operate with precision and perform specific movements, creating better interventional conditions. Thanks to its open architecture, R-One is compatible with market-leading devices and cath labs.
“Strokes are currently the second most common cause of death worldwide. However, there is huge inequality in terms of care provision. The success of treatment is highly dependent on the operator’s level of experience and the proximity of a center capable of treating the condition. Our robotic solution will enable procedures to be more precise and more reliable, which will benefit stroke patients by greatly improving their treatment. Linked with our remote connection module, in the future our technology could treat 100 percent of patients in the best possible conditions,” Robocath CEO Lucien Goffart said.
In a prospective, randomized, controlled pre-clinical trial, R-One demonstrated safety and efficacy as it achieved 100 percent technical procedure success and no major adverse cardiovascular events. R-One received CE marking in February 2019 and started its clinical application in September 2019. Currently R-One is available in Europe and Africa.
“Robocath’s founding ambition was to ensure the best possible treatment for all stroke patients. For the first time in the company’s history, this procedure has made that ambition a reality," Robocath President/Founder Philippe Bencteux said. "It is a major step forward in our development; opening up some very promising new possibilities for our next robotic generation. I would like to thank Dr. Eugène for his involvement. With his support, as well as that of Philips France, we intend to showcase the huge potential of robotics in the neurovascular field.”
Founded in 2009, Robocath designs, develops, and commercializes robotic solutions to treat cardiovascular diseases. Based in Rouen, France, Robocath has more than 60 employees.